CYP2C9


CYP2C9
Cytochrome P450, family 2, subfamily C, polypeptide 9

Ribbon diagram of CYP2C9, heme group visible at center. From PDB 1OG2.
Identifiers
Symbols CYP2C9; CPC9; CYP2C; CYP2C10; CYPIIC9; MGC149605; MGC88320; P450IIC9
External IDs OMIM601130 MGI103238 HomoloGene110445 GeneCards: CYP2C9 Gene
RNA expression pattern
PBB GE CYP2C9 214421 x at tn.png
PBB GE CYP2C9 216025 x at tn.png
PBB GE CYP2C9 216661 x at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 1559 13095
Ensembl ENSG00000138109 ENSMUSG00000003053
UniProt P11712 Q3UEF2
RefSeq (mRNA) NM_000771.3 NM_007815
RefSeq (protein) NP_000762.2 NP_031841
Location (UCSC) Chr 10:
96.7 – 96.75 Mb
Chr 19:
39.34 – 39.38 Mb
PubMed search [1] [2]

Cytochrome P450 2C9 (abbreviated CYP2C9) is a protein that in humans is encoded by the CYP2C9 gene.[1][2]

Contents

Function

CYP2C9 is an important cytochrome P450 enzyme with a major role in the oxidation of both xenobiotic and endogenous compounds. CYP2C9 makes up about 18% of the cytochrome P450 protein in liver microsomes. Some 100 therapeutic drugs are metabolized by CYP2C9, including drugs with a narrow therapeutic index such as warfarin and phenytoin and other routinely prescribed drugs such as acenocoumarol, tolbutamide, losartan, glipizide, and some nonsteroidal anti-inflammatory drugs. By contrast, the known extrahepatic CYP2C9 often metabolizes important endogenous compound such as arachidonic acid , 5-hydroxytryptamine, and linoleic acid.[3]

Pharmacogenomics

Genetic polymorphism exists for CYP2C9 expression because the CYP2C9 gene is highly polymorphic. More than 50 single nucleotide polymorphisms (SNPs) have been described in the regulatory and coding regions of the CYP2C9 gene,[4] some of them are associated with reduced enzyme activity compared with wild type in vitro.[citation needed]

Multiple in vivo studies also show that several mutant CYP2C9 genotypes are associated with significant reduction of in metabolism and daily dose requirements of selected CYP2C9 substrate. In fact, adverse drug reactions (ADRs) often result from unanticipated changes in CYP2C9 enzyme activity secondary to genetic polymorphisms. Especially for CYP2C9 substrates such as warfarin and phenytoin, diminished metabolic capacity because of genetic polymorphisms or drug-drug interactions can lead to toxicity at normal therapeutic doses.[5][6]

Allele frequencies(%) of CYP2C9 polymorphism

African-American Black-African Pygmy Asian Caucasian
CYP2C9*2 2.9 0-4.3 0 0-0.1 8-19
CYP2C9*3 2.0 0-2.3 0 1.1-3.6 3.3-16.2
CYP2C9*5 0-1.7 0.8-1.8 ND 0 0
CYP2C9*6 0.6 2.7 ND 0 0
CYP2C9*7 0 0 6 0 0
CYP2C9*8 1.9 8.6 4 0 0
CYP2C9*9 13 15.7 22 0 0.3
CYP2C9*11 1.4-1.8 2.7 6 0 0.4-1.0
CYP2C9*13[7] ND ND ND 0.5-0.6 ND

CYP2C9 Ligands

Most inhibitors of CYP2C9 are competitive inhibitors. Noncompetitive inhibitors of CYP2C9 include nifedipine,[8] tranylcypromine,[9] phenethyl isothiocyanate,[10] medroxyprogesterone acetate[11] and 6-hydroxyflavone. It was indicated that the noncompetitive binding site of 6-hydroxyflavone is the reported allosteric binding site of the CYP2C9 enzyme.[12]

Following is a table of selected substrates, inducers and inhibitors of CYP2C9. Where classes of agents are listed, there may be exceptions within the class.

Inhibitors of CYP2C9 can be classified by their potency, such as:

  • Strong being one that causes at least a 5-fold increase in the plasma AUC values, or more than 80% decrease in clearance.[13]
  • Moderate being one that causes at least a 2-fold increase in the plasma AUC values, or 50-80% decrease in clearance.[13]
  • Weak being one that causes at least a 1.25-fold but less than 2-fold increase in the plasma AUC values, or 20-50% decrease in clearance.[13]
Selected inducers, inhibitors and substrates of CYP2C9
Substrates Inhibitors Inducers
Strong:

Moderate

Unspecified potency

Strong:

See also

  • Cytochrome P450 oxidase

References

  1. ^ Romkes, Marjorie; Faletto, Michael B.; Blaisdell, Joyce A.; Raucy, Judy L.; Goldstein, Joyce A. (1991). "Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily". Biochemistry 30 (13): 3247–55. doi:10.1021/bi00227a012. PMID 2009263. 
  2. ^ Inoue, Kiyoshi; Inazawa, Johji; Suzuki, Yasuhiko; Shimada, Tsutomu; Yamazaki, Hiroshi; Guengerich, F. Peter; Abe, Tatsuo (1994). "Fluorescencein situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1". The Japanese Journal of Human Genetics 39 (3): 337–43. doi:10.1007/BF01874052. PMID 7841444. 
  3. ^ Rettie, Allan E.; Jones, Jeffrey P. (2005). "CLINICAL AND TOXICOLOGICAL RELEVANCE OF CYP2C9: Drug-Drug Interactions and Pharmacogenetics". Annual Review of Pharmacology and Toxicology 45: 477–94. doi:10.1146/annurev.pharmtox.45.120403.095821. PMID 15822186. 
  4. ^ Sim, Sarah C (2-May-2011). "CYP2C9 allele nomenclature". Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.cypalleles.ki.se/cyp2c9.htm. [self-published source?]
  5. ^ García-Martín, E; Martínez, C; Ladero, JM; Agúndez, JA (2006). "Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals". Molecular diagnosis & therapy 10 (1): 29–40. PMID 16646575. 
  6. ^ Rosemary, J.; Adithan, C. (2007). "The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance". Current Clinical Pharmacology 2 (1): 93–109. doi:10.2174/157488407779422302. PMID 18690857. 
  7. ^ Si, Dayong; Guo, Yingjie; Zhang, Yifan; Yang, Lei; Zhou, Hui; Zhong, Dafang (2004). "Identification of a novel variant CYP2C9 allele in Chinese". Pharmacogenetics 14 (7): 465–9. doi:10.1097/01.fpc.0000114749.08559.e4. PMID 15226678. 
  8. ^ Bourrié, Martine; Meunier, Viviane; Berger, Yves; Fabre, Gérard (1999). "Role of Cytochrome P-4502C9 in Irbesartan Oxidation by Human Liver Microsomes". Drug Metabolism and Disposition 27 (2): 288–96. PMID 9929518. http://dmd.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9929518. 
  9. ^ Salsali, Mahnaz; Holt, Andrew; Baker, Glen B. (2004). "Inhibitory Effects of the Monoamine Oxidase Inhibitor Tranylcypromine on the Cytochrome P450 Enzymes CYP2C19, CYP2C9, and CYP2D6". Cellular and Molecular Neurobiology 24 (1): 63–76. doi:10.1023/B:CEMN.0000012725.31108.4a. PMID 15049511. 
  10. ^ Nakajima, Miki; Yoshida, Ryoko; Shimada, Noriaki; Yamazaki, Hiroshi; Yokoi, Tsuyoshi (2001). "Inhibition and Inactivation of Human Cytochrome P450 Isoforms by Phenethyl Isothiocyanate". Drug Metabolism and Disposition 29 (8): 1110–3. PMID 11454729. http://dmd.aspetjournals.org/cgi/pmidlookup?view=long&pmid=11454729. 
  11. ^ Zhang, Jiang-Wei; Liu, Yong; Li, Wei; Hao, Da-Cheng; Yang, Ling (2006). "Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes". European Journal of Clinical Pharmacology 62 (7): 497–502. doi:10.1007/s00228-006-0128-9. PMID 16645869. 
  12. ^ a b c Si, D.; Wang, Y.; Zhou, Y.-H.; Guo, Y.; Wang, J.; Zhou, H.; Li, Z.-S.; Fawcett, J. P. (2008). "Mechanism of CYP2C9 Inhibition by Flavones and Flavonols". Drug Metabolism and Disposition 37 (3): 629–34. doi:10.1124/dmd.108.023416. PMID 19074529. 
  13. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar Flockhart DA (2007). "Drug Interactions: Cytochrome P450 Drug Interaction Table". Indiana University School of Medicine. http://medicine.iupui.edu/flockhart/table.htm. 
  14. ^ a b c d e f g h i j k l m n o p q r s t u FASS (drug formulary): "Facts for prescribers (Fakta för förskrivare)" (in Swedish). Swedish environmental classification of pharmaceuticals. http://www.fass.se/LIF/produktfakta/fakta_lakare_artikel.jsp?articleID=18352. 
  15. ^ Guo, Y.; Zhang, Y; Wang, Y; Chen, X; Si, D; Zhong, D; Fawcett, JP; Zhou, H (2005). "ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C9*3 AND CYP2C9*13) IN THE METABOLISM OF LORNOXICAM IN HUMANS". Drug Metabolism and Disposition 33 (6): 749–53. doi:10.1124/dmd.105.003616. PMID 15764711. 
  16. ^ Kimura, Yuka; Ito, Hideyuki; Ohnishi, Ryoko; Hatano, Tsutomu (2010). "Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity". Food and Chemical Toxicology 48 (1): 429–35. doi:10.1016/j.fct.2009.10.041. PMID 19883715. 
  17. ^ Pan, Xulin; Tan, Ninghua; Zeng, Guangzhi; Zhang, Yumei; Jia, Ruirui (2005). "Amentoflavone and its derivatives as novel natural inhibitors of human Cathepsin B". Bioorganic & Medicinal Chemistry 13 (20): 5819–25. doi:10.1016/j.bmc.2005.05.071. PMID 16084098. 
  18. ^ a b He, Nu; Zhang, Wen-Qi; Shockley, Dolores; Edeki, Timi (2002). "Inhibitory effects of H 1 -antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes". European Journal of Clinical Pharmacology 57 (12): 847–51. doi:10.1007/s00228-001-0399-0. PMID 11936702. 
  19. ^ Park, J.-Y.; Kim, K.-A.; Kim, S.-L. (2003). "Chloramphenicol Is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes". Antimicrobial Agents and Chemotherapy 47 (11): 3464–9. doi:10.1128/AAC.47.11.3464-3469.2003. PMC 253795. PMID 14576103. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=253795. 

Further reading

External links


Wikimedia Foundation. 2010.

Look at other dictionaries:

  • CYP2C9 — Saltar a navegación, búsqueda Diagrama del CYP2C9, el grupo hemo visible en el centro. CYP2C9 Identificadores Símbolo …   Wikipedia Español

  • CYP2C9*13 — Cytochrome P450 2C9 (CYP2C9), a member of theCYP2C enzyme subfamily, ranks amongst the mostimportant drug metabolizing enzymes in humans. Human CYP2C9 has been shown to exhibit genetic polymorphism. In addition to the wild type protein CYP2C9*1,… …   Wikipedia

  • CYP2C9*3 — Cytochrome P450 2C9 (CYP2C9), a member of theCYP2C enzyme subfamily, ranks amongst the mostimportant drug metabolizing enzymes in humans. Human CYP2C9 has been shown to exhibit genetic polymorphism. In addition to the wild type proteinCYP2C9*1,… …   Wikipedia

  • Траклир — Действующее вещество ›› Босентан* (Bosentan*) Латинское название Tracleer АТХ: ›› C02KX01 Бозентан Фармакологическая группа: Другие сердечно сосудистые средства Состав и форма выпуска Таблетки, покрытые оболочкой1 табл.босентан (в форме… …   Словарь медицинских препаратов

  • Estatina — Saltar a navegación, búsqueda Est …   Wikipedia Español

  • Вифенд — Действующее вещество ›› Вориконазол* (Voriconazole*) Латинское название Vfend АТХ: ›› J02AC03 Вориконазол Фармакологическая группа: Противогрибковые средства Нозологическая классификация (МКБ 10) ›› A41 Другая септицемия ›› B37 Кандидоз ›› B37.7… …   Словарь медицинских препаратов

  • Warfarin — This article is about the drug with the brandname Coumadin. For the anticoagulant rodenticide poisons often called coumarins or coumadins , see 4 hydroxycoumarins. Warfarin …   Wikipedia

  • Benzbromarone — Systematic (IUPAC) name (3,5 dibromo 4 hydroxyphenyl) (2 ethyl 3 benzofuranyl)methanone Clinical data AHFS/Drugs.com …   Wikipedia

  • Интеленс — Действующее вещество ›› Этравирин* (Etravirine*) Латинское название Intelence АТХ: ›› J05AG Ненуклеозиды — ингибиторы обратной транскриптазы Фармакологическая группа: Средства для лечения ВИЧ инфекции Нозологическая классификация (МКБ 10)… …   Словарь медицинских препаратов

  • Non-competitive inhibition — is a type of enzyme inhibition where the inhibitor reduces the activity of the enzyme, by binding not to the active site on the enzyme, but to a different site.[1] More specifically, it is a special instance of mixed inhibition where the… …   Wikipedia


Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.